Drug Type ASO |
Synonyms |
Target |
Mechanism MALAT1 inhibitors(metastasis associated lung adenocarcinoma transcript 1 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization Flamingo Therapeutics BVStartup |
Active Organization Flamingo Therapeutics BVStartup |
Inactive Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Triple Negative Breast Cancer | Preclinical | BE | Flamingo Therapeutics BVStartup | 25 Apr 2024 |
Neoplasms | Preclinical | BE | Flamingo Therapeutics BVStartup | 14 Apr 2023 |